Childhood Absence Epilepsy Treatment Market Predicts Rise In Demand By 2026; Major Players Dominate The Market

Coherent Market Insights has announced the addition of the “Childhood Absence Epilepsy Treatment Market, By Drug (Ethosuximide, Valproate, Lamotrigine, and Phase 2 Drugs (Cannabidiol Oral Solution and CX-8998)), By Disease Type (Typical Absence Seizures and Atypical Absence Seizures), and By Region (North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2018 – 2026”, The report classifies the Childhood Absence Epilepsy Treatment Market in a precise manner to offer detailed insights into the aspects responsible for augmenting as well as restraining market growth.

Download PDF Brochure of Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/2329

Absence seizures (previously known as petit-mal) are commonly found in children than in adults with frequent occurrence. The seizures of childhood absence epilepsy often start between the ages of 4 to 7 years. It rarely starts before 4 years of age and late as 8 years of age. Seizures can occur many times a day ranging from 10 to 100 times a day, known as pyknolepsy. Seizures are divided into typical and atypical absence seizures depending on the nature of the seizures. As symptoms of some other medical conditions are similar to epilepsy, diagnosing epilepsy proves to be difficult. Some protocols should be followed by the patient such as maintaining a diary of seizure occurrence dates, time, and detailed description for easier diagnosis. Seizures should be diagnosed and classified by seizure type and syndrome. Ethosuximide is generally the first choice of treatment for childhood absence epilepsy Ethosuximide is very effective in typical absence seizures. Although Ethosuximide and Valproate are found to be similarly effective, Ethosuximide is better accepted by patients. Atypical absence seizures have been found to respond well to Valproic acid. Lamotrigine is considered after both the drugs Ethosuximide and Valproate, as lamotrigine is found to have low efficacy than the other drugs.

Market Dynamics:

Key players in the market are focused on the development of new drugs for the treatment of childhood absence epilepsy. Factors such as increasing prevalence of the disease, increasing accessibility of medications, and presence of drugs in the pipeline for childhood absence epilepsy treatment (Insys therapeutics and Cavion, Inc.) are expected to boost the global childhood absence epilepsy treatment market growth. Product launches by generic manufacturers in the U.S. as well as globally is expected to support the growth of the market. For instance, Dr. Reddy’s Laboratories launched generic lamotrigine orally disintegrating tablets in the U.S. in 2016. Moreover, a number of manufacturers such as Insys Therapeutics (Cannabidiol) and Cavion, Inc. (CX-8998) have drugs in phase II stage in clinical trials and these therapies are expected to be launched over the forecast period.

High prevalence of epilepsy and seizures among children is expected to drive global childhood absence epilepsy treatment market growth over the forecast period

Epilepsy is a highly prevalent disorder, especially in emerging economies. The incidence and prevalence of epilepsy in children appear to be lower in developed economies and highest in rural areas of underdeveloped economies. For instance, according to the World Health Organization (WHO), February 2018, around 80% of the people suffering from epilepsy live in low– and middle- income countries. According to the American Academy of Pediatrics in April 2017, epilepsy affects 0.5% to 1% of children, globally and is the most frequent chronic neurologic condition observed in childhood. Only around one-third of children with epilepsy can be assigned to a specific epilepsy type, as defined by the recently proposed system for classification of epilepsy syndrome (ILAE Classification of epilepsies). According to the Society of Neuroscience in 2015, epilepsy affects an estimated 10.5 million children worldwide, and the types and severity of the disorder vary significantly. According to the National Center for Biotechnology Information (NCBI), 2013, around 10% of seizures in children with epilepsy are typical absence seizures.

The global childhood absence epilepsy treatment market was valued at US$ 158.2 million in 2017 and is expected to witness a robust CAGR of 5.4% over the forecast period (2018 – 2026).

Childhood Absence Epilepsy Treatment Market - Competitive Landscape

Some of the major players operating in the global childhood absence epilepsy treatment market include Cavion, Inc., Pfizer, Inc., GlaxoSmithKline Plc, Insys Therapeutics, Inc., AbbVie, Inc., and Teva Pharmaceutical Industries Ltd.

Detailed Segmentation:

Global Childhood Absence Epilepsy Treatment Market, By Drug:

• Ethosuximide
• Valproate
• Lamotrigine
• Phase 2 Drugs
- Cannabidiol Oral Solution
- CX-8998

Global Childhood Absence Epilepsy Treatment Market, By Disease Type:

• Typical Absence Seizures
• Atypical Absence Seizures

Global Childhood Absence Epilepsy Treatment Market, By Region:

• North America
• Latin America
• Europe
• Asia Pacific
• Middle East
• Africa

Wish to Buy this report, click here @ https://www.coherentmarketinsights.com/insight/buy-now/2329

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com